TRIB Key Statistics, Chart & Performance
The current stock price of TRIB is 0.8811 USD. In the past month the price increased by 7.45%. In the past year, price decreased by -80.42%.
TRIB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to TRIB. When comparing the yearly performance of all stocks, TRIB is a bad performer in the overall market: 93.76% of all stocks are doing better.
TRIB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TRIB. TRIB may be in some trouble as it scores bad on both profitability and health.
TRIB Financial Highlights
Over the last trailing twelve months TRIB reported a non-GAAP Earnings per Share(EPS) of -2.68. The EPS increased by 16.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.78% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TRIB Forecast & Estimates
For the next year, analysts expect an EPS growth of 65.8% and a revenue growth 10.13% for TRIB
TRIB Ownership
About TRIB
Company Profile
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Company Info
TRINITY BIOTECH PLC-SPON ADR
Ida Business Park, Bray, Co Wicklow
DUBLIN WICKLOW IE
CEO: Ronan O'Caoimh
Employees: 401
Phone: 1135312955111
TRINITY BIOTECH PLC-SPON ADR / TRIB FAQ
What does TRIB do?
Trinity Biotech Plc engages in the development, manufacture, and marketing of medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. The firm develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.
Can you provide the latest stock price for TRINITY BIOTECH PLC-SPON ADR?
The current stock price of TRIB is 0.8811 USD. The price decreased by -2.88% in the last trading session.
What is the dividend status of TRINITY BIOTECH PLC-SPON ADR?
TRIB does not pay a dividend.
What is the ChartMill rating of TRINITY BIOTECH PLC-SPON ADR stock?
TRIB has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is TRIB stock listed?
TRIB stock is listed on the Nasdaq exchange.
Can you provide the ownership details for TRIB stock?
You can find the ownership structure of TRINITY BIOTECH PLC-SPON ADR (TRIB) on the Ownership tab.